Aim. To assess the effects of combination therapy with ACE inhibitors and carvedilol on cardiac remodeling, cardiac arrhythmias, and quality of life (QoL) in patients with mild to moderate chronic heart failure (CHF).Material and methods. The study included 109 patients with mild to moderate CHF, developed in arterial hypertension, coronary heart disease, or their combination with diabetes mellitus and obesity. Initial carvedilol dose was 6,25-25 mg/d. At baseline, 3, 6, and 9 months later, physical examination, biochemical assay, lectrocardiography,QoL and clinical outcome assessment were performed. Doppler echocardiography and 24-hour electrocardiogram (ECG) monitoring were performed at baseline and 6 months later.Results. CHF therapy, including the combination of ACE inhibitor and carvedilol, was associated with reduction in structural left ventricular (LV) remodeling, as well as with systolic and diastolic LV function normalization. According to 24-hour ECG monitoring data, the total number of supraventricular (including paired and grouped) and ventricular (including paired ectopic complexes) extrasystoles significantly decreased. Combination, carvedilol-including CHF therapy resulted in significant QoL and clinical prognosis improvement.Conclusion. In patients with mild to moderate CHF, carvedilol demonstrated its clinical effectiveness, including reduced structural and electric remodeling progression
